ArticleCase reports in endocrinology2026
Nonmetastatic Pulmonary Carcinoid Presenting With Carcinoid Syndrome Despite Negative 5-HIAA: A Case Report.
Article in Case reports in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nonmetastatic Pulmonary Carcinoid Presenting With Carcinoid Syndrome Despite Negative 5-HIAA: A Case Report.Case reports in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carcinoid syndrome from pulmonary carcinoids without hepatic metastases is rare and diagnostically challenging when biochemical markers are normal. Case Presentation: A woman in her mid-60 s presented with an incidental right adrenal mass during evaluation for dyspnea and elevated D-dimer. She reported a 20-year history of paroxysmal tachycardia and 5 years of episodic flushing, profuse sweating, exertional dyspnea, and fine tremors triggered by minimal physical activity. Imaging revealed a 3.6 cm lipid-rich adrenal adenoma and an 8 × 10 mm left upper lobe pulmonary nodule. Comprehensive biochemical evaluation was normal: 24 h urinary 5-hydroxyindoleacetic acid 6 mg/d (normal 0-15), chromogranin A 50 ng/mL (normal 0-187), plasma metanephrine 0.12 nmol/L (normal 0.00-0.49), and normetanephrine 0.68 nmol/L (normal 0.00-0.89), excluding pheochromocytoma. Fine needle aspiration of the left pulmonary nodule confirmed a typical carcinoid tumor. Left upper lobe trisegmentectomy revealed low-grade neuroendocrine neoplasm (pT1b pN0) with minimal mitotic activity (<1 per 10 HPF) and no necrosis. Postoperative 68Ga-DOTATATE PET/CT demonstrated a radiotracer-avid suspicious right lower lobe nodule (SUVmax 2.8) without hepatic metastases. Surgery markedly improved carcinoid syndrome symptoms, with residual episodes responding to long-acting octreotide 20-30 mg every 4 weeks. Discussion: This case illustrates that pulmonary carcinoid tumors can present with carcinoid syndrome despite normal biochemical markers and the absence of hepatic metastases. The temporal improvement following resection and response to octreotide established the diagnosis when biochemical testing was uninformative. Conclusion: Clinicians should maintain high suspicion for pulmonary carcinoids in patients with unexplained paroxysmal symptoms, even with negative biochemical testing and absent metastatic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.